Compass Pathways (CMPS) shares remain below $20 at end of Q3 2026 absent a regulatory de-risking catalyst.

Compass Pathways (ticker: CMPS) is a company developing psilocybin-based treatments. Its stock price tends to move based on excitement and news, not profits. Without a major win — like an FDA approval or a strong late-stage clinical trial result — there's no obvious reason the stock would break above $20 before the end of September 2026.

Small-cap psychedelic equities trade on momentum, not fundamentals; without an FDA approval or Phase 3 readout materially de-risking the program, CMPS lacks a driver to rerate above the $20 threshold near-term.